SUPERCENTENARIAN INDUCED PLURIPOTENT STEM (sciPS) CELLS AND METHODS OF MAKING AND USING THEREOF

Abstract

Provided herein are cells and methods for reprogramming iPS cells from a supercentenarian and their differentiated, derivatives having differences from non-supercentenarian iPS derived cells that contribute to disease resistance and longevity. Additionally, provided herein are methods for treatment and prevention of age related diseases by administration of therapeutic sciPS derived cells or cell derived reagents. Also provided herein, are methods for identifying reagents for treatment of age related diseases using sciPS cell-based assays.

What is claimed is: 
     
         1 . A. method of generating stem cells having a reduced rate of cellular aging; the method comprising:
 a. collecting a cell sample from a validated supercentenarian individual:   b. reprogramming cells from the cell sample into induced pluripotent (iPS) cells;   c. identifying supercentenarian induced pluripotent stem (sciPS) cells which exhibit telomere length resetting; and   d. deriving stems cells winch exhibit telomere length resetting from the sciPS cells, thereby generating stem cells having a reduced, rate of cellular aging as compared to stem cells from iPS cells from a non-supercentenarian donor.   
     
     
         2 . The method of  claim 1 , wherein the sciPS cells exhibit full telomere length resetting towards embryonic length. 
     
     
         3 . The method of  claim 1 , wherein the supercentenarian individual is a human. 
     
     
         4 . The method of  claim 1 , wherein the stem cells are mesenchymal stromal cells (MSC) or hematopoietic stem cells (HSC). 
     
     
         5 . The method of  claim 1 , wherein cells from the cell sample are selected from the group consisting of blood cells, dermal fibroblasts, adipose cells and hair follicle cells. 
     
     
         6 . An isolated population of sciPS cells comprising iPS cells from a supercentenarian individual, wherein the iPS cells exhibit telomere length resetting. 
     
     
         7 . The sciPS cells of  claim 6 , wherein the iPS cells exhibit telomere length resetting towards embryonic length. 
     
     
         8 . The sciPS cells of  claim 6 , wherein the supercentenarian individual is a human. 
     
     
         9 . An isolated population of stem cells derived from the sciPS cells of  claim 6 ; wherein the stem cells exhibit telomere length resetting. 
     
     
         10 . A method of identifying substances capable of tissue homeostasis and immune function regulation; the method comprising:
 a. culturing sciPS cells according to  claim 6  and stem cells therefrom in growth media; and   b. identifying substances in the growth media or in cell extracts.   
     
     
         11 . A method of age-related disease relevant screening of candidate agents; the method comprising:
 a. contacting the candidate agent with a population of stem cells exhibiting telomere length resetting, wherein the stem cells are from sciPS cells having a reduced rate of cellular aging as compared to non-sciPS cells; and   b. determining the morphologic, genetic, or functional effect of the candidate agent on the stem cells or on cells differentiated therefrom.   
     
     
         12 . The method of  claim 11 , wherein the age-related disease is selected from the group consisting of osteoporosis, osteoarthritis, cancer, heart disease, stroke, and neurological disorders. 
     
     
         13 . The method of  claim 11 , wherein the candidate agent is selected from the group consisting of biologies, small molecules, drugs, nutraceuticals, cosmeceuticals, compounds, and reagents. 
     
     
         14 . The method of  claim 11 , wherein the stem cells are human stem cells. 
     
     
         15 . The method of  claim 11 , wherein the stem cells exhibit full telomere length resetting towards embryonic length. 
     
     
         16 . The method of  claim 11 , wherein the stem cells are MSCs or HSCs. 
     
     
         17 . A method of screening candidate agents capable of conferring sciPS benefits to non-sciPS cells; the method comprising:
 a. contacting the candidate agent with a population of non-sciPS cells; and   b. identifying agents which are capable of conferring sciPS benefits to the non-sciPS cells,   
     
     
         18 . The method of  claim 17 , wherein the candidate agent is selected from the group consisting of biologies, small molecules, drugs, nutraceuticals, cosmeceuticals, compounds, and reagents. 
     
     
         19 . The method of  claim 17 , wherein the sciPS benefits conferred to the non-sciPS cells are a reduced rate of cellular aging as compared to non-sciPS cells without the candidate assent. 
     
     
         20 . The method of  claim 17 , wherein the non-sciPS cells are human.